Gastro-esophageal Cancers at the Interface of Biology and New Therapeutic Options

Wael El-Rifai, M.D., Ph.D.

Senior Chair in Cancer Research
Associate Director for Basic Science
Associate Vice Chair of Surgery
Professor of Biochemistry and Molecular Biology
University of Miami

CLICK HERE to View Recording

Objectives

At the end of the presentation, participants will be able to:

• Explain molecular changes in gastro-esophageal cancers and druggable targets
• Analyze chemotherapeutic resistance
• Illustrate novel approaches to overcome resistance to chemotherapeutics and Immune check point therapies

Faculty Disclosure

Dr. El-Rifai has indicated that he has no relevant financial relationships with commercial interests.

Planning Committee Disclosure

Dr. Lekakis has indicated that he has no relevant financial relationships with commercial interests.

Target Audience

Faculty, Primary Care Physicians, APRNs, PharmD

Accreditation

The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.